^
Association details:
| Biomarker: | Chr amplification(1q) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | VRD (bortezomib + dexamethasone injection + lenalidomide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone
Published date:
11/01/2018
Excerpt:
Of 1000 total myeloma patients treated with RVD induction, 146 (14.6%) were noted to have +1q by FISH...Median PFS was significantly shorter for patients with +1q compared with those without +1q (41.8 months vs 86.0 months , respectively, HR 2.39, p<0.001 ). OS of patients with +1q was significantly worse than patients without +1q...In this retrospective, single-center analysis of multiple myeloma patients treated with RVD induction, patients with 1q amplification had similar responses to induction therapy, but significantly inferior PFS and OS compared to patients without +1q.
